Pain Management Therapeutics Market growing CAGR of (5.5%) from 2013 to 2019. By Transparency Market Research

Transparency Market Research is Published new Market Report “Pain Management Therapeutics Market- Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 - 2018," in 2011, the global pain management therapeutics market was valued at USD 40.93 billion and is expected to decline at a CAGR of (5.5%) from 2012 to 2018, to reach an estimated value of USD 29.47 billion in 2018.

The global pain management therapeutics market is expected to experience a decline in revenues at a CAGR of (5.5%) during the forecast period, mainly due to patent expirations of the leading branded drugs. Although the global incidence rates of cancer, diabetes and other debilitating diseases that cause various chronic pain conditions is on a rise, the decline in market revenue is inevitable due to generic incursion for the top pain management drugs. Moreover, lack of a strong pipeline of novel or combination drugs that could help restore the positive growth of the overall market is also expected to contribute to the overall decline in the global pain management therapeutics market.

Administration of analgesics is the first line of treatment for the management of acute as well as chronic pain conditions. Some of the factors driving the growth of this market

include the favorable regulatory and healthcare reforms such as the U.S. Patient Protection and Affordable Care Act of 2010. Also, the economic and effective nature of treatment with therapeutics compared to other modes, such as neurostimulation devices and acupuncture, will continue to fuel the uptake of drugs in pain management.

The market for non-steroidal anti-inflammatory drugs (NSAIDs) accounted for the largest share by revenue in 2011, of the total pain management therapeutics market by therapeutic class. This class comprises of some of the oldest known painkillers such as diclofenac, ibuprofen and Aspirin (acetylsalicylic acid) which are now commonly available as over-the-counter (OTC) medications, globally. However, the patent expiry of Celebrex (celecoxib) in 2013 is expected to negatively impact the market with a decline in revenues post patent expiry. The class of other non-narcotic analgesics consists of acetaminophen, sold as OTC drugs in the names of Tylenol, Panadol and Excedrin, and is expected to record the highest CAGR of 3.1% during the forecast period. Increase in the uptake of OTC drugs across the globe to overcome common pain conditions such as headache and body ache, will be responsible for this growth. The loss of patent exclusivity of other key brands such as Cymbalta (duloxetine), OxyContin (oxycodone) and Lidoderm (lidocaine) scheduled in the year 2013 will have a profound impact on the growth of the overall market.

North America was the largest regional market by revenue in 2011, due to the presence of one or more branded drugs belonging to each therapeutic class. However, the region is expected to record the lowest CAGR due to the looming patent expiries of these brands.

The market for generic formulations accounted for a larger share of the overall pain management therapeutics market in 2011, as against branded formulations. The market for branded pharmaceuticals was highly fragmented in 2011, with Pfizer, Inc., Purdue Pharma LP and Eli Lilly & Co. contributing to over 80% of the total market revenue. Other important players in this market include Endo Health Solutions, AstraZeneca PLC, Johnson & Johnson, and Merck & Co., Inc.

The pain management therapeutics market is segmented as follows:

Pain Management Therapeutics Market, by Therapeutic Class

• Anticonvulsants
• Antidepressants
• Anesthetics
• NSAIDs
• Opioids
• Other Non-Narcotic Analgesics (Acetaminophen)

• Anti-Migraine Agents

Pain Management Therapeutics Market, by Indication

• Neuropathic Pain
• Fibromyalgia
• Arthritic Pain, by Type
• Osteoarthritis
• Rheumatoid Arthritis
• Chronic Back Pain
• Migraine
• Post-operative Pain
• Cancer Pain

Pain Management Therapeutics Market, by Geography

• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

TABLE OF CONTENTS :

Chapter 1 Preface

1.1 Report Description

1.2 Market Segmentation

1.3 Research Methodology

Chapter 2 Executive Summary

Browse the full report at  http://www.transparencymarketresearch.com/pain-management-therapeutics.html

Chapter 3 Market Overview

3.1 Introduction to Pain Management – Types of Treatments

3.2 World Health Organization’s “Pain Ladder” for cancer

3.3 Market Trends and Future Outlook

       3.3.1 Impact of generics

       3.3.2 Key patent expirations

3.4 Market Drivers

       3.4.1 Global increasing incidence of chronic pain disorders

       3.4.2 Favorable regulatory scenario and healthcare reforms

       3.4.3 Easy and effective medications

       3.4.4 Impact analysis of market drivers

3.5 Market Restraints

       3.5.1 Prescription drug abuse

       3.5.2 Pain advocacy groups losing power, influence and funding

       3.5.3 Adulteration and fake drugs thrive in developing regions

       3.5.4 Long term pain relief from surgical procedures, alternative therapies and medical devices

       3.5.5 Impact analysis of market restraints

3.6 Market Opportunities

       3.6.1 Novel molecule combinations and drug delivery techniques are expected to become a rising opportunity in forecast period

       3.6.2 Generics expected to be a rising opportunity globally

 3.7 Porter’s Five Forces Analysis

       3.7.1 Bargaining power of buyers

       3.7.2 Bargaining power of suppliers

       3.7.3 Threat of substitutes

       3.7.4 Threat of new entrants

       3.7.5 Competitive rivalry

3.8 Market Attractiveness Analysis: Global Pain Management Therapeutics Market, By Geography (2011)

Chapter 4 Global Pain Management Therapeutics Market, by Therapeutic Class

4.1 Anticonvulsants

       4.1.1 Current and future market scenario

4.2 Antidepressants

       4.2.1 Current market scenario and patent expiry effect

       4.2.2 Future market scenario

4.3 Anesthetics

       4.3.1 Current market scenario and patent expiry effect

       4.3.2 Pipeline drugs and their effect

       4.3.3 General Anesthetics

       4.3.4 Local Anesthetics

4.4 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

       4.4.1 Current market scenario and patent expiry effect

4.5 Opioids

       4.5.1 Current market scenario and patent expiry effect

       4.5.2 Pipeline drugs and their effect on the market

                4.5.2.1 MoxDuo IR

               

              4.5.2.2 Remoxy

4.6 Anti-Migraine Agents

       4.6.1 Pipeline drugs and additional approvals

4.7 Other Non-Narcotic Analgesics (Acetaminophen)

Chapter 5 Global Pain Management Therapeutics Market, by Indication

5.1 Neuropathic Pain

5.2 Fibromyalgia

5.3 Arthritic Pain

       5.3.1 Osteoarthritis (OA)

       5.3.2 Rheumatoid Arthritis (RA)

5.4 Chronic Back Pain

5.5 Migraine

5.6 Post-operative pain

5.7 Cancer Pain

Chapter 6 Global Pain Management Therapeutics Market, by Geography

6.1 Overview

       6.1.1 Global Pain Management Therapeutics Market, by Geography, Size and Forecast, 2010 – 2018 (USD Million)

       6.1.2 Comparative Analysis: Global Pain Management Therapeutics Market, by Geography, 2011 & 2018 (Value %)

6.2 North America

       6.2.1 North America Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.3 Europe

       6.3.1 Europe Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.4 Asia-Pacific

       6.4.1 Asia-Pacific Pain Management Therapeutics  Market, by Therapeutic Class, Size and Forecast, 2010 - 2018 (USD Million)

6.5 Rest of the World (RoW)

       6.5.1 RoW Pain Management Therapeutics Market, by Therapeutic Class, Size and 

Forecast, 2010 - 2018 (USD Million)

Chapter 7 Competitive Landscape

7.1 Market Share Analysis: Global Pain Management Therapeutics Market (2011)

       7.1.1 Market Share by Marketing Status (Branded & Generic Pharmaceuticals), 2011 (%)

       7.1.2 Market Share by Key Players: Branded Pharmaceuticals, 2011 (%)

7.2 Pipeline Snapshot: Pain Management Therapeutics

       7.2.1 MoxDuo (morphine and oxycodone)

       7.2.2 Remoxy (oxycodone)

       7.2.3 Posidur (SABER-bupivacaine)

       7.2.4 Zecuity (transdermal sumatriptan)

Chapter 8 Recommendations

8.1 Development of novel combination formulations

8.2 Addressing unmet needs: drug abuse and side-effects

8.3 Generics manufacturers: Investment in emerging markets such as India, China and Russia

8.4 Mergers and acquisitions to enter or strengthen market presence

Chapter 9 Company Profiles

9.1 Abbott Laboratories

       9.1.1 Company Overview

       9.1.2 Financial Overview

       9.1.3 Product Portfolio

       9.1.4 Business Strategies

       9.1.5 Recent Developments

9.2 Allergan, Inc.

       9.2.1 Company Overview

       9.2.2 Financial Overview

       9.2.3 Product Portfolio

       9.2.4 Business Strategies

       9.2.5 Recent Developments

9.3 Covidien plc

       9.3.1 Company Overview

       9.3.2 Financial Overview

       9.3.3 Product Portfolio

       9.3.4 Business Strategies

       9.3.5 Recent Developments

9.4 Durect Corporation

       9.4.1 Company Overview

       9.4.2 Financial Overview

       9.4.3 Pipeline Products

       9.4.4 Business Strategies

       9.4.5 Recent Developments

9.5 Eli Lilly and Company

       9.5.1 Business Overview

       9.5.2 Financial Overview

       9.5.3 Product Portfolio

       9.5.4 Business Strategies

       9.5.5 Recent Developments

9.6 Endo Health Solutions, Inc.

       9.6.1 Company Overview

       9.6.2 Financial Overview

       9.6.3 Product Portfolio

       9.6.4 Business Strategies

       9.6.5 Recent Developments

9.7 Forest Laboratories, Inc.

       9.7.1 Company Overview

       9.7.2 Financial Overview

       9.7.3 Product Portfolio

       9.7.4 Business Strategies

       9.7.5 Recent Developments

9.8 GlaxoSmithKline plc

       9.8.1 Company Overview

       9.8.2 Financial Overview

       9.8.3 Product Portfolio

       9.8.4 Business Strategies

       9.8.5 Recent Developments

9.9 Hospira, Inc.

       9.9.1 Company Overview

       9.9.2 Financial Overview

       9.9.3 Product Portfolio

       9.9.4 Business Strategies

       9.9.5 Recent Developments

9.10 Johnson & Johnson

       9.10.1 Company Overview

       9.10.2 Financial Overview

       9.10.3 Product Portfolio

       9.10.4 Business Strategies

       9.10.5 Recent Developments

9.11 Merck & Co., Inc.

       9.11.1 Company Overview

       9.11.2 Financial Overview

       9.11.3 Product Portfolio

       9.11.4 Business Strategies

       9.11.5 Recent Developments

9.12 Mundipharma International Ltd.

       9.12.1 Company Overview

       9.12.2 Financial Overview

       9.12.3 Product Portfolio

       9.12.4 Business Strategies

       9.12.5 Recent Developments

9.13 Novartis  International AG

       9.13.1 Company Overview

       9.13.2 Financial Overview

       9.13.3 Product Portfolio

       9.13.4 Business Strategies

       9.13.5 Recent Developments

9.14 NuPathe, Inc.

       9.14.1 Company Overview

       9.14.2 Financial Overview

       9.14.3 Product Portfolio

       9.14.4 Business Strategies

       9.14.5 Recent Developments

9.15 Pain Therapeutics, Inc.

       9.15.1 Company Overview

       9.15.2 Financial Overview

       9.15.3 Product Portfolio

       9.15.4 Business Strategies

       9.15.5 Recent Developments

9.16 Pfizer, Inc.

       9.16.1 Company Overview

       9.16.2 Financial Overview

       9.16.3 Product Portfolio

       9.16.4 Business Strategies

       9.16.5 Recent Developments

9.17 Purdue Pharma L.P.

       9.17.1 Company Overview

       9.17.2 Financial Overview

       9.17.3 Product Portfolio

       9.17.4 Business Strategies

       9.17.5 Recent Developments

9.18 QRx Pharma Ltd.

       9.18.1 Company Overview

       9.18.2 Financial Overview

       9.18.3 Product Portfolio

       9.18.4 Business Strategies

       9.18.5 Recent Developments

9.19 Sanofi

       9.19.1 Company Overview

       9.19.2 Financial Overview

       9.19.3 Product Portfolio

       9.19.4 Business Strategies

       9.19.5 Recent Developments

9.20 Teva Pharmaceutical Industries Limited

       9.20.1 Company Overview

       9.20.2 Financial Overview

       9.20.3 Product Portfolio

       9.20.4 Business Strategies

       9.20.5 Recent Developments

9.21 UCB (Union Chemnique Belge) S.A.

       9.21.1 Company Overview

       9.21.2 Financial Overview

       9.21.3 Product Portfolio

       9.21.4 Business Strategies

       9.21.5 Recent Developments

About Us:

Transparency Market Research is a market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers.

We are privileged with highly experienced team of Analysts, Researchers and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Renal Denervation (RDN) Devices Market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from 2013 to 2019 to reach an estimated value of USD 2,937.3 million by 2019.

Transparency Market Research Report Add "Renal Denervation Devices  Market -Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 – 2019" to its database.

 Renal Denervation (RDN) Devices Market was valued at USD 760 million and is expected to grow at a CAGR of 21.3% from 2013 to 2019 to reach an estimated value of USD 2,937.3 million by 2019.

Browse the full report at  http://www.transparencymarketresearch.com/renal-denervation-devices-market.html 

The global market for RDN devices is expected to grow with increasing incidences of hypertension and aging population. Due to high level of safety and reduced treatment time, RDN procedure is expected to dominate over the drug treatment method for uncontrolled hypertension. Increasing market collaboration among the industry players to introduce better technology will help gain a competitive advantage in this booming market.

Radiofrequency RDN (RF-RDN) devices segment represented the largest segment by technology in 2012 and is expected to continue this trend till 2021. Owing to safety, time efficiency and reproducibility, RF-RDN devices have gained popularity in the global market. Despite having several benefits, manufacturers are struggling to get marketing approval for their devices. Radiofrequency RDN devices segment will face strong competition from emerging technologies such as ultrasound, cryoablation, microfusion, radiation and nano-particles.

The global renal denervation market is currently dominated by Europe due to large number of device approvals and R&D activities conducted by industry players. Europe accounts for more than 80% of the market share and is estimated to maintain its dominating position through 2021. The major market for RDN devices are Germany, France, UK and Italy. Asia-Pacific is the second largest and fastest regional market for RDN devices. The RDN devices market in North America is expected to gain rapid pace from 2015 as many devices are in the pipeline to receive FDA approvals.

The report estimates the renal denervation market by product of each major company. It also gives a detailed analysis over a period of nine years with updates and expected outcomes in the coming years. The research report is specially designed to analyze the demand and performance of RDN devices in the global market, providing in-depth analysis of the trends, on-going developments, factors driving the demand of RDN devices, and the restraints for the RDN devices market. The market is estimated and analyzed by segmenting it into technology, products (by manufacturers), and geography. The sub-segments included under each of these groups are as follows:

• By technology
• Radiofrequency-based RDN system
• Ultrasound-based RDN System
• Micro-infusion RDN system
• By products
• Medtronic's Symplicity
• St. Jude's EnlighHTN
• Boston Scientific's (Vessix Vascular) V2
• Covidien's OneShot
• ReCor Medical's Paradise
• By geography
• North America
• Europe
• Asia-Pacific
• Rest of the World (RoW)

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Visit: http://www.transparencymarketresearch.com/

Life Sciences BPO market is growing at a CAGR of 21.5% from 2013 to 2019.By Transparency Market Research

Global Life Sciences BPO market was valued at USD 152.5 billion in 2012 and is estimated to reach a market value worth USD 596.0 billion in 2019, growing at a CAGR of 21.5% from 2013 to 2019.

Browse Life Sciences BPO Market Report with Full TOC at http://www.transparencymarketresearch.com/life-sciences-bpo-market.html

Rising cost, growing complexities of conducting clinical trials and increased pressure from regulatory agencies to adopt various techniques to minimize the costs involved for successful introduction of a drug in the market has compelled pharmaceutical players to adopt new outsourcing models. All these factors have helped fuel market growth of the Life Sciences BPO industry in the past decade. In addition, rise in the number of patent expirations and failure of drugs during the clinical trials process has triggered the overall growth of pharmaceutical outsourcing industry. Moreover, outsourcing aids the biotechand pharmaceutical industry to focus on their core strategies and utilize their internal resources for more critical in-house projects.

The Contract Manufacturing Organizations (CMOs) outsourcing services accounts for the largest segment of the overall Life Sciences BPO market. Growing healthcare costs has led to a rise in the demand for generic drugs and this has consequently led to growth in demand for active pharmaceutical outsourcing services. Moreover, CMOs conduct internal R&D to come up with novel technologies to further support their clients. The API manufacturing market accounts to be largest segment of the total CMO market. This growth has been attributed to increase in outsourcing activities for pharmaceutical manufacturing outsourcing, owing to increasing regulatory compliance such cGMP and other approvals. Moreover, manufacturers do not have all the technologies and expertise available in-house required for manufacturing different APIs and hence, outsourcing serves as a more cost effective solution for pharmaceutical companies. Also, the growing importance of biological drugs calls for distinctive manufacturing technology.

The Contract Research Organizations (CROs) outsourcing services market has also witnessed significant growth in the past decade. This growth has been attributed to the rising costs involved in conducting various phases of clinical trials ranging from drug discovery up to post marketing approvals. Pharmaceutical companies are now opting to outsource their clinical trial activities to vendor scapable of providing bundled services such as regulatory services, clinical data management, medical writing, site management, pharma covigilance, risk based monitoring, biostatics, protocol development and others. The drug discovery services segment accounted for the largest market share in 2012.Since a large number of molecules fail during the drug discovery process, through outsourcing the pharmaceutical companies are mitigating their financial risks and avoiding sunken costs through partnership with CROs. However, clinical data management outsourcing services market is expected to foresee the highest growth rate of 17.3% from 2013 to 2019. This high growth has been attributed to the growing adoption of advanced IT services such cloud applications and enhanced software services provided by Information Technology Outsourcing (ITO). Data security and Intellectual Property Rights (IPR)still persist to be major hindrance for growth of this industry.

Geographically, North America accounted for the largest share of the global pharmaceutical outsourcing services market in 2012 and was valued at USD 28.4 billion in 2012 followed by Asia-Pacific. The Asian-Pacific region is expected to represent the highest growth rate of 21.2% during the forecast period owing to availability of trained resources, low cost labor, favorable regulatory policies and huge patient pool suffering from varies chronic diseases. Moreover, the companies from this region are now meeting the required manufacturing and quality standards of the USFDA and EMEA to further boost market growth.

The major players in this market include Catalent Pharma Solutions, Lonza Group, Parexel International, PRA International, Piramal Healthcare, Charles River Laboratories, PPD (Pharmaceutical Product Development), Cognizant, Accenture, IBM, Quintiles, Covance and others.

Global Life Sciences BPO Market, by Segments

o    Pharmaceutical Outsourcing Market

o    Contract Manufacturing Organizations (CMOs)

o    Active Pharmaceutical Ingredients (APIs) Manufacturing

o    Finished Dosage Formulation (FDF) Development and Manufacturing

o    Packaging

o    Contract Research Organizations (CROs)

o    Drug Discovery

o    Pre-Clinical Studies

o    Clinical Studies

o    Medical Writing

o    Clinical Data Management (CDM)

o    Bio-Statistics

o    Risk Based Monitoring

o    Site Management

o    Pharmacovigilance

o    Regulatory Services

o    Protocol Development

o    Others

o    Contract Sales Organizations (CSOs)

Global Life Sciences BPO Market, by Geography

o    North America

o    Europe

o    Germany

o    France

o    U.K.

o    Italy

o    Spain

o    Switzerland

o    ROE

o    Asia-Pacific

o    Rest of the World

Browse all Pharmaceutical Market Research Reports @ http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.html

About Us

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact
Sheela AK
90 Sate Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Web: http://www.transparencymarketresearch.com/